Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of BI 1569912 in Healthy Male Japanese Subjects
NCT04958252Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1569912 (9 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Subjects With Drug-related Adverse Events (SRD Part) at 48 hours, Number of Subjects With Drug-related Adverse Events (MD Part) at 16 days and 2 more. Started Aug 2021; status: completed.
02
Drugs
BI 1569912
Beyond the preview
Go deeper on NCT04958252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04958252.